D&D Pharmatech
KOE: 347850.KQ0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Seul-ki Lee
- Employees
- 21
- Headquarters
- Seongnam-si, South Korea
- IPO year
- 2024
- Market cap
- ₩3.1T
- Website
- https://www.ddpharmatech.com
Loading 347850…
Loading profile data…Frequently asked questions about 347850
What does D&D Pharmatech (347850.KQ) do?
D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson's disease (PD), Alzheimer's disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to...
Where does 347850.KQ trade?
D&D Pharmatech (347850.KQ) trades on the KOSDAQ.
What sector is 347850.KQ in?
D&D Pharmatech (347850.KQ) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of D&D Pharmatech?
Seul-ki Lee is the chief executive officer of D&D Pharmatech (347850.KQ).
Where is D&D Pharmatech headquartered?
D&D Pharmatech is headquartered in South Korea.
Does 347850.KQ pay a dividend?
D&D Pharmatech (347850.KQ) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 347850.KQ go public?
D&D Pharmatech (347850.KQ) completed its initial public offering in 2024.